Recursion Pharmaceuticals, Inc.
https://www.recursion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Recursion Pharmaceuticals, Inc.
Finance Watch: US Market May Warm To Go-Public Options As Summer Progresses
Public Company Edition: The IPO market in the US cooled in Q2, but a warm-up may come in Q3 alongside new SPAC merger opportunities; Artiva may be the next biopharma firm to go public. Also, IDEAYA and Recursion grossed $302.4m and $200m, respectively, in follow-on offerings.
Finance Watch: Two New VC Funds Bring $365m For Start-Ups
Private Company Edition: Amplitude Ventures raised $192m for its second fund, while XGEN Venture debuted with €160m ($173.4m). Also, hub-and-spoke biopharma operator CinRx added $73m, Adcendo extended its series A round to €98m ($106.2m) and Grey Wolf raised $50m.
Korea Looks To Close Gap In AI Drug Development Capabilities
Syntekabio CSO HeaKyoung Cho talks to Scrip how the AI-driven drug development situation in Korea compares with global trends and what the domestic industry needs to do to survive rising competition at home and abroad.
Isomorphic Boasts Its Latest AI Tool
AlphaFold 3 is promising, but for now it stays in the hands of Isomorphic Labs and its partners.
Company Information
- Industry
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Drug Discovery Technologies
- Bioinformatics
-
Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Recursion Pharmaceuticals, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice